Coronavirus Vaccine at Least a Year Away: NIH Official

Dr. Anthony Fauci (R), director of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health (NIH), and Dr. Anne Schuchat (L), of the Centers for Disease Control and Prevention (CDC), testify about the Zika virus during a Senate Health, Education, Labor and Pensions committee hearing on Capitol Hill in Washington, DC, February 24, 2016.  (SAUL LOEB/AFP via Getty Images)

No major pharmaceutical company has come forward to say it would manufacture a novel coronavirus vaccine, currently being developed by the National Institutes of Health, a top U.S. official acknowledged Tuesday, a reality that he called “very difficult and very frustrating.”

The comments by Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, highlight how challenging it could be to translate the NIH’s work, being undertaken in partnership with the biotech company Moderna Therapeutics, into a vaccine that could be marketed. Fauci described the circumstances as challenging. “Companies that have the skill to be able to do it are not going to just sit around and have a warm facility, ready to go for when you need it,” Fauci said, speaking on a panel Tuesday hosted by the Aspen Institute and moderated by STAT’s Helen Branswell.

Fauci said it would be at least a year before a coronavirus vaccine would be available. However, that timeline assumes a large pharmaceutical manufacturer does step up to help make the product.

The vaccine being developed by the NIH and Moderna uses mRNA technology and is being funded by the Oslo, Norway-based Coalition for Epidemic Preparedness Innovations. CEPI is funding three other efforts to develop a vaccine for the novel coronavirus. None of those partners, however, have the kind of commercial facilities that major pharmaceutical makers have and that would be capable of making the product in bulk.

Johnson & Johnson has announced it is interested in developing its own coronavirus vaccine. On Tuesday, the company’s vaccine division, Janssen, said it would partner with the Biomedical Advanced Research and Development Authority, an agency of the Department of Health and Human Services to develop that vaccine.

Sponsored

In a statement, the agency’s director, Rick Bright, said “speed is crucial to saving lives and reducing further spread of the virus. Janssen is a proven partner with a flexible, rapid, vaccine platform.”

Major drug makers, including Merck and GlaxoSmithKline, have stepped in to manufacture vaccines for previous public health emergencies. The vaccine against Ebola recently approved by the Food and Drug Administration and European regulators was manufactured by Merck.

At other times, however, companies have responded in public health crises to develop vaccines, only to have those crises fade and to be left with the enormous sunk costs of having to develop products for which there was no longer a market.

“When we were doing this with Ebola, it was a major vaccine company that got burned who’s now pulling out of that,” Fauci added, without naming the company. “It is going to be a challenge to be able to get a major company to do that.”

Speaking alongside Fauci at the event was Ron Klain, who served as Ebola czar in the Obama administration and who echoed concerns that drug makers may be wary of getting involved again.

“I don’t work for the companies, I’m not like a drug company fan,” Klain said, “but there’s no question that a lot of them lost a lot of money trying to produce an Ebola vaccine.”

This story was originally published by STAT, an online publication of Boston Globe Media that covers health, medicine, and scientific discovery.

Volume
KQED Live
Live Stream
Log In ToPledge-Free Stream
LATEST NEWSCAST
KQED
NPR
Live Stream information currently unavailable.
Share
LATEST NEWSCAST
KQED
NPR
KQED Live

Live Stream

Live Stream information currently unavailable.